Clinical technology advances driving in vivo CAR therapy
Yan-Ruide Li, Yichen Zhu, Lili Yang
Abstract
In vivo chimeric antigen receptor (CAR) engineering has advanced into clinical trials with encouraging safety and efficacy. Technology breakthroughs, including targeted lipid nanoparticles, genetically modified lentiviruses, and optimized CAR constructs, have enabled precise, efficient, and safe gene delivery. This forum summarizes innovations accelerating the clinical translation of in vivo CAR engineering for immunotherapy.
Topics & Concepts
Chimeric antigen receptorIn vivoGenetic enhancementMedicineClinical trialGenetically engineeredSafety profileTranslation (biology)BioinformaticsComputational biologyGene technologyPreclinical researchTranslational researchPharmacologyBiotechnologyPharmaceutical technologyEngineeringVirus-based gene therapy researchCAR-T cell therapy researchRNA Interference and Gene Delivery